AWM
JAZZ icon

Affinity Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Affinity Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$497K Hold
2,627
– – 0.08% 58
2025
Q4 		$447K Hold
2,627
– – 0.06% 63
2025
Q3 		$346K Hold
2,627
– – 0.05% 72
2025
Q2 		$279K Buy
+2,627
New +$285K 0.04% 85

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Affinity Wealth Management's JAZZ Position: Q1 2026 in Review

Affinity Wealth Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q1 2026 at 2,627 shares worth $497K. The position accounts for 0.08% of the portfolio, ranked #58.

Affinity Wealth Management first reported a position in JAZZ in Q2 2025 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Affinity Wealth Management held 2,627 shares of Jazz Pharmaceuticals worth $497K as of Q1 2026.
  • Affinity Wealth Management left its Jazz Pharmaceuticals share count unchanged in Q1 2026.
  • Jazz Pharmaceuticals made up 0.08% of Affinity Wealth Management's portfolio in Q1 2026, its #58 holding.
  • Affinity Wealth Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Affinity Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.